

ENROLLMENT FORM

Today's Date: _____
Needed By: _____

Last update 12.04.2018

Patient Demographics: (Please provide the following or attach demographics sheet)		Provider Office: (Please provide as much information as possible)	
Patient Name: _____		Prescriber's Name: _____ Group/Hospital: _____	
Address: _____		Specialty: _____ License#: _____ Tax ID#: _____	
City, State, Zip: _____		Address: _____	
Preferred Phone: _____ Alt. Phone: _____		NPI: _____ DEA: _____	
Last four digits of SS#: _____ Date of Birth: _____		City, State, Zip: _____	
Gender: _____ Allergies: _____ Height: _____ Weight: _____		Phone: _____ Fax: _____ Office Contact: _____	

Insurance Information: (Please copy and attach the front and back of the patient's insurance card)

Medication Delivery to: (choose one) Patient's Address Always to Physician's Office First fill to Physician's Office, refills to Patient's Address

Diagnostic Information: Diagnosis (ICD-10-CM codes) K50.0 Regional Enteritis or Crohn's of Small Intestine K51.90 Ulcerative Colitis
 K50.10 Regional Enteritis or Crohn's of Large Intestine K50.90 Regional Enteritis or Crohn's Disease NOS Other: _____
 Date of Diagnosis: _____ OR Years with Disease: _____

Injection Training & Education Needs: Specialty Pharmacy Injection Training Manufacturer's Patient Assistance Program Enrollment
 Prescriber's office will train patient Prescriber's office already trained patient Patient is already independently injecting

Requested Clinical Information: (as applicable) Does patient have a latex allergy? Yes No
 Has Hepatitis B been ruled out? Yes No Does patient have serious/active infection? Yes No Has TB test been performed? Yes No If Yes, Results _____

Previous Therapies:

Drug Name	Strength	Directions	Quantity	Refill
<input type="checkbox"/> Cimzia®	<input type="checkbox"/> Cimzia Starter Kit (6 syringes) <input type="checkbox"/> Prefilled Syringe 200mg/ML (2 syringes) <input type="checkbox"/> Lyophilized powder pack (2 x 200mg/vial)	INITIAL: <input type="checkbox"/> Inject 400mg SQ at weeks 0,2, & 4 MAINTENANCE: <input type="checkbox"/> Inject 400mg SQ every 4 weeks <input type="checkbox"/> Inject 200mg SQ every 2 weeks <input type="checkbox"/> Other: _____	INITIAL: <input type="checkbox"/> Starter kit x 1 (6 PFS) <input type="checkbox"/> 3 boxes (6 vials) MAINTENANCE: <input type="checkbox"/> 4 week supply <input type="checkbox"/> Other: _____	
<input type="checkbox"/> Humira®	Citrate Free Starter Kit <input type="checkbox"/> 80mg/0.8mL CD PEDIATRIC #3 PFS <input type="checkbox"/> 80mg/0.8mL+40mg/0.4mL CD PEDIATRIC #2 PFS <input type="checkbox"/> 80mg/0.8mL CD/UC/HS #3 PEN Citrate Free Maintenance Kit <input type="checkbox"/> 10mg/0.1mL PFS <input type="checkbox"/> 20mg/0.2mL PFS <input type="checkbox"/> 40mg/0.4mL PEN <input type="checkbox"/> 40mg/0.4mL PFS Non-Citrate Free Starter Kit <input type="checkbox"/> 40mg/0.8mL CD/UC/HS PEDIATRIC #6 PFS <input type="checkbox"/> 40mg/0.8mL CD/UC/HS PEDIATRIC #3 PFS <input type="checkbox"/> 40mg/0.8mL CD/UC/HS #6 PEN Non-Citrate Free Maintenance Kit <input type="checkbox"/> 10mg/0.2mL PFS <input type="checkbox"/> 20mg/0.4mL PFS <input type="checkbox"/> 40mg/0.8mL PEN <input type="checkbox"/> 40mg/0.8mL PFS	Adult INITIAL: Inject 160mg SQ on day 1, then 80mg on day 15, then maintenance on day 29 MAINTENANCE: Inject 40mg SQ every OTHER week <input type="checkbox"/> Other: _____ Child 17kg (37lbs) to <40kg (88lbs) INITIAL: Inject 80mg SQ on day 1, then 40mg on day 15, then maintenance on day 29 MAINTENANCE: Inject 20mg SQ every OTHER week Child ≥ 40kg (88lbs) MAINTENANCE: Inject 160mg SQ on day 1, then 80mg on day 15, then maintenance on day 29 MAINTENANCE: Inject 40mg SQ every OTHER week <input type="checkbox"/> Other: _____	INITIAL: <input type="checkbox"/> Starter kit x 1 MAINTENANCE: <input type="checkbox"/> 4 week supply <input type="checkbox"/> Other: _____	
<input type="checkbox"/> Simponi®	<input type="checkbox"/> 100mg/mL SmartJect Autoinjector <input type="checkbox"/> 100mg/mL Prefilled Syringe	INITIAL: Inject 200mg SQ at week 0, 100mg at week 2, then maintenance dose at week 6 MAINTENANCE: Inject 100mg SQ every 4 weeks <input type="checkbox"/> Other: _____	INITIAL: <input type="checkbox"/> 3 SmartJect Autoinjectors <input type="checkbox"/> 3 Prefilled Syringes MAINTENANCE: <input type="checkbox"/> 4 week supply <input type="checkbox"/> Other: _____	
<input type="checkbox"/> Stelara®	<input type="checkbox"/> 90mg/mL Prefilled Syringe	MAINTENANCE: Inject 90mg SQ every 8 weeks <input type="checkbox"/> Other: _____	MAINTENANCE: 8 weeks <input type="checkbox"/> Other: _____	
<input type="checkbox"/> Xeljanz®	<input type="checkbox"/> 5mg Tablet <input type="checkbox"/> 10mg Tablet	<input type="checkbox"/> Take 10mg by mouth TWICE daily <input type="checkbox"/> Other: _____	<input type="checkbox"/> 30 day supply <input type="checkbox"/> Other: _____	
<input type="checkbox"/> Other			PFS = prefilled syringe, PEN = prefilled pen CD = Crohn's Disease, UC = Ulcerative Colitis, SQ = subcutaneously	

Unless otherwise noted this prescription authorizes Acro and Commcare to dispense & share information between each other to optimize care delivery. Check here to restrict to Acro Commcare

Physician Signature: _____ DAW (Dispense as Written) **Date:** _____

Patient Support Programs: I authorize Acro Pharmaceutical Services and Commcare Specialty Pharmacy to enroll me in company-assisted patient support program, corresponding with my prescribed therapy for purposes of receiving additional services such as, but not limited to injection training. I further authorize the release to communicate to the corresponding manufacturer the minimum necessary information about my health condition and prescription(s) to: coordinate the delivery of products and services available through the patient assistance program, aggregate de-identified data for market analysis or other commercial purposes, and provide educational information regarding therapies. I understand that I may refuse to sign this authorization and that my refusal will not affect my ability to obtain treatment from the pharmacy. However, I will not be enrolled in the service program listed above. A copy of this authorization will be utilized with same effectiveness as an original. Ancillary supplies provided as needed for administration.

***Patient Signature:** (required for participation): _____ **Date:** _____ Please select if you would like the patient enrolled in a Manufacturer's Assistance Program
CONFIDENTIALITY NOTICE: If you are not the intended recipient or the person responsible for delivering it to the intended recipient, you are hereby notified that you are not authorized to read, print, retain, copy or disseminate this message, any part of it, or any attachments. This facsimile message may contain information that is confidential, privileged, proprietary, or otherwise legally exempt from disclosure or use. Any disclosure or use of this facsimile message by any person other than the intended recipient or person responsible for delivering it to the intended recipient may constitute a Federal criminal offense punishable by imprisonment up to 10 years or fines up to \$250,000. If you have received this message in error, please destroy this message and any accompanying attachments in their entirety without reading the content and notify the sender immediately by telephone of the inadvertent transmission, by calling collect if located outside the calling area. There is no intent on the part of the sender to waive any right or privilege that may be attached to this communication. Thank you for your cooperation. *This prescription is valid only if transmitted by means of a facsimile machine from the authorized prescriber.